Phaseline

Companies › Hangzhou Gensciences Biopharmaceutical

Hangzhou Gensciences Biopharmaceutical: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 3; Hematology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
FRSW107
Recombinant human coagulation Factor VIII-Fc fusion protein
F8Phase 3Severe Hemophilia AFeb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07663903FRSW107Phase 3Severe Hemophilia AHematologyFeb 2027
NCT07684898FRSW107Phase 3Severe Hemophilia AHematologyMar 2027

Targets

F8 (1)

Companies with the same targets

Pfizer Roche Swedish Orphan Biovitrum Sinocelltech Octapharma ASC Therapeutics Bioverativ, a Sanofi company Biocad Gritgen Therapeutics Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical

Companies built like this

Bioverativ, a Sanofi company Gritgen Therapeutics Forma Therapeutics Wuhan Createrna Science and Technology Pharmanutra

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.